Ligand raises 2025 revenue and EPS guidance to $225M and $7 amid royalty portfolio momentum
Source: SeekingAlpha
2025-08-07 20:02:19 ET
More on Ligand Pharmaceuticals
- Ligand Pharmaceuticals Incorporated 2025 Q2 - Results - Earnings Call Presentation
- Ligand Pharmaceuticals Incorporated (LGND) Q2 2025 Earnings Call Transcript
- Ligand Pharmaceuticals: Attractive Royalty Model Powers Forward
- Ligand Pharmaceuticals beats Q2 expectations, raises guidance
- Ligand Pharmaceuticals Q2 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Ligand raises 2025 revenue and EPS guidance to $225M and $7 amid royalty portfolio momentum
Ligand Pharms Inc Cvr
NASDAQ: LGNDZ
LGNDZ Trading
0.0% G/L:
$0.002 Last:
7,245 Volume:
$0.002 Open:
LGNDZ Latest News
LGNDZ Stock Data
$3,679,103,920
18,304,000
N/A
151
N/A
Biotechnology & Life Sciences
Healthcare
US
Jupiter
